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Abstract
Screening of biomarker expression levels in tumor biopsy samples not only provides an assessment of prognostic and
predictive factors, but may also be used for selection of biomarker-specific imaging strategies. To assess the feasibility of
using a biopsy specimen for a personalized selection of an imaging agent, the chemokine receptor 4 (CXCR4) was used as a
reference biomarker.Methods: A hybrid CXCR4 targeting peptide (MSAP-Ac-TZ14011) containing a fluorescent dye and a
chelate for radioactive labeling was used to directly compare initial flow cytometry–based target validation in fresh tumor
tissue to in vivo single photon emission computed tomography (SPECT) imaging and in vivo and ex vivo fluorescence
imaging.
Results: Flow cytometric analysis of mouse tumor derived cell suspensions enabled discrimination between 4T1 control
tumor lesions (with low levels of CXCR4 expression) and CXCR4 positive early, intermediate and late stage MIN-O lesions
based on their CXCR4 expression levels; CXCR4
basal, CXCR4
+ and CXCR4
++ cell populations could be accurately
discriminated. Mean fluorescent intensity ratios between expression in MIN-O and 4T1 tissue found with flow cytometry
were comparable to ratios obtained with in vivo SPECT/CT and fluorescence imaging, ex vivo fluorescence evaluation and
standard immunohistochemistry.
Conclusion: The hybrid nature of a targeting imaging agent like MSAP-Ac-TZ14011 enables integration of target selection,
in vivo imaging and ex vivo validation using a single agent. The use of biopsy tissue for biomarker screening can readily be
expanded to other targeting hybrid imaging agents and can possibly help increase the clinical applicability of tumor-
specific imaging approaches.
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Introduction
Screening of biomarker expression levels in breast cancer biopsy
samples using immunohistochemistry (IHC) is a routine procedure
that provides an assessment of prognostic and predictive factors
such as histological grade, subtype and hormone receptor and
human epidermal growth factor receptor 2 (Her2/neu) status
[1,2]. The molecular insights derived from these biopsy samples
can be used for decision-making in (personalized) treatment
planning. For example, estrogen receptor (ER) and/or the Her2/
neu status in biopsy samples can predict the response to
trastuzumab when added to standard cytotoxic adjuvant chemo-
therapy [3–5]. Additionally, staining of biopsy tissue for less
established biomarkers such as the chemokine receptor 4
(CXCR4) has been shown to correlate with aggressiveness/
invasiveness and metastatic potential in breast cancer [6–8].
The current standard of care in (preoperative) non-invasive
imaging of breast cancer includes implementation of contrast
enhanced MRI and
18F-FDG PET. Both modalities are widely
applied in the detection of cancer and many other diseases. They
rely on differences in perfusion/vascular ‘‘leakiness’’ (MRI) and
metabolism/glucose uptake (PET) between diseased and normal
tissue. For more specific visualization of e.g. tumor tissue, at
present, numerous alternative imaging agents are being developed
which directly target specific biomarkers expressed on the cell
membrane.
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e48324Expression patterns of such biomarkers tend to be heteroge-
neous and vary between patients and tumor subtypes, which could
also imply the need for more than one targeting compound for
accurate imaging-based assessment of a specific tumor lesion.
However, realistically, one cannot perform consecutive biomarker
screening studies in a single patient. Similar to their use in
treatment selection, individual biomarker expression patterns may
also be exploited for specific imaging strategies, as was shown by
Dijkers et al. who performed non-invasive positron emission
tomography (PET) imaging of Her2/neu positive lesions in
patients with metastatic breast cancer [9].
Identification of a biomarker or rather a diagnostic target
during the different logistical steps in clinical management viz.
IHC of biopsy tissue, (preoperative) imaging, intraoperative
surgical guidance and pathological evaluation of resection
margins, are all commonly performed using different methods
and different (targeting) compounds. This variation may lead to a
discrepancy in findings. In an ideal situation, however, target
selection and further follow-up are conducted using one and the
same imaging agent. This should yield more interchangeable and
complementary results during the whole logistical process of
cancer management (Fig. 1). For this reason a ‘‘smart’’ screening
method for an imaging approach or a combination thereof is
required.
We have recently demonstrated the clinical value of hybrid
tracers. The hybrid tracer ICG-
99 mTc-nanocolloid, enables both
the diagnostic identification of sentinel lymph nodes (radioactive
component;
99 mTc) and provides optical guidance during the
surgical resection (fluorescent component; ICG) [10–15]. This
hybrid surgical guidance approach has already been applied in
over 300 patients and for a number of different tumor locations.
Integration of this concept with a (tumor) targeting moiety will aid
in the resection of primary tumors and metastases [16].
For a targeted imaging approach a tailored selection process
that identifies the best diagnostic target will be instrumental for the
successful application of biomarker specific imaging agents. With
this in mind we reasoned that a biopsy specimen can potentially be
used for the selection of a specific imaging agent.
To demonstrate the feasibility of integrating biopsy screening in
fresh breast tumor tissue with in vivo imaging, the chemokine
receptor 4 (CXCR4) was used as a reference biomarker. In a
recent critical review, in which we evaluated CXCR4 targeting
imaging agents based on their affinity, specificity and biodistribu-
tion, the T140 peptide derivative Ac-TZ14011 was shown to be
one of the best targeting moieties for evaluation of CXCR4
expression levels using fluorescence imaging [17]. Different
imaging labels on the Ac-TZ14011 peptide have been shown to
aid the specific visualization of CXCR4 expressing tumor cells
with: i) fluorescence IHC (FITC labeled version), ii) flow
cytometric analysis (FITC labeled version), iii) SPECT/CT
(
111In-DTPA labeled version) and iv) in vivo fluorescence imaging
(near-infrared labeled version) [18–20]. The synthetic develop-
ment of a hybrid version of this targeting peptide (MSAP-Ac-
TZ14011), which contains both a fluorescent label and a chelate
for radioactive labeling, enabled integration of in vitro affinity
evaluation and in vivo imaging methods [21,22].
In this study the concept of using a biopsy specimen for a
personalized selection of the most optimal targeting imaging
approach was evaluated using MSAP-Ac-TZ14011. The fluores-
cent label was used to assess the membranous CXCR4 expression
pattern in fresh tumor segments obtained from tumor bearing
mice. After radioactive labeling with 111-indium, the same
imaging agent was suitable for in vivo SPECT/CT imaging.
The initial screening results obtained with flow cytometry (Fig. 1A)
were directly correlated to in vivo imaging results (SPECT/CT and
fluorescence imaging; Fig. 1B), and microscopic ex vivo analysis
(fluorescence confocal microscopy; Fig. 1C); hereby comprising all
steps in clinical cancer management.
Materials and Methods
Synthesis and radiolabeling of MSAP-Ac-TZ14011
MSAP-Ac-TZ14011 (Fig. 2) was synthesized and radiolabeled
according to previously described procedures [22].
In vivo model
As a CXCR4 positive tumor model the orthotopic MIN-O
transplantation model resembling human ductal carcinoma in situ
was used [23,24]. In this model, preinvasive lesions progress into
invasive lesions with increasing membranous CXCR4 expression
[19]. Tumor lesions were staged according to previously reported
criteria; based on CT-based size measurements and IHC
discrimination was made between early stage (,100 mm
3),
intermediate stage (100–400 mm
3), and late stage (.400 mm
3)
lesions [19].
Cell line based 4T1 tumor lesion served as control. In these
control tumors, CXCR4 expression is constantly low during tumor
progression [19] and therefore no discrimination between stages
was made. 4T1 cells (from American Type Culture Collection,
ATCC) were a kind gift of dr. O. van Tellingen, NKI-AvL,
Amsterdam, The Netherlands.
All tumor lesions were generated as reported previously [19].
Animal experiments were performed in accordance with Dutch
welfare regulations and were approved by the ethics committee of
the Netherlands Cancer Institute under references 08021 B19 and
08021 B21. Implantation of tumor tissue or cells and in vivo
imaging were performed under hypnorm/dormicum/water (1:1:2;
5 mL/g i.p.) anesthesia. All efforts were made to minimize
suffering.
Fresh tumor tissue analysis
From fresh tumor specimens (MIN-O: n=6 per stage; 4T1:
n=6) single cell suspensions were made by cutting the tumor into
small pieces with a scalpel and suspending them using a 18G, 21G
and a 25G needle, respectively. The cell suspension was incubated
for 5 minutes with an ER-lysis buffer (0.31 M NH4Cl, 0.02 M
KHCO3, 0.5 M EDTA in 2 L H2O; pH 7.4) to remove red blood
cells. 300,000 cells per measuring condition were washed with
0.1% bovine serum albumin in phosphate buffered saline (0.1%
BSA/PBS) and incubated for 1 hour at 4uC under dark conditions
with MSAP-Ac-TZ14011 (1:200 from a stock of 1 mg/mL) or
with the monoclonal phycoerythrin (PE) labeled anti-CXCR4
antibody 2B11 (2B11-PE; 1:100; BD Biosciences). For evaluation
of the overlap in staining between MSAP-Ac-TZ14011 and 2B11-
PE, cells were co-incubated with MSAP-Ac-TZ14011 and 2B11-
PE.
Following incubation cells were washed with 0.1% BSA/PBS
and propidium iodide (PI; 1:10.000; BD Biosciences) was added to
allow the selection of viable cells. Antibodies were diluted in 0.1%
BSA/PBS in all flow cytometric experiments. Non-peptide/
antibody incubated cells served as controls. Cells were analyzed
(approximately 20,000 events per sample) using a CyAn ADP
flowcytometer (DakoCytomation) equipped with Summit v4.3
sorftware (DakoCytomation). PE fluorescence was detected after
excitation at 488 nm. Emission was collected at 575/25 nm. PI
was detected after excitation at 488 nm and emission was collected
at 613/20 nm. The CyAL-5.5b dye on the MSAP label was exited
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was comparable between samples.
For evaluation of CXCR4 staining, stained populations were
divided into CXCR4
2 (CXCR4 negative cells), CXCR4
basal
(basal/low expression of CXCR4), CXCR4
+ and CXCR4
++,
based on the measured cell surface associated fluorescence;
populations were discriminated based on differences in the mean
fluorescence of that specific population. Mean fluorescence
intensity ratios (MFIR) were calculated by dividing the mean
fluorescence intensity of all cells stained by MSAP-Ac-TZ14011 by
the mean fluorescence intensity of the non-incubated control. The
ratio between the MIN-O and 4T1 tumor lesion was determined
by dividing the MFIR of the various MIN-O tumor lesions by
MFIR of the 4T1 tumor lesion. The ratio between the
CXCR4
basal and the CXCR4
+ and CXCR4
++ populations was
determined by calculating the MFIR between the CXCR4
+ or
CXCR4
++ and the CXCR4
basal population. This results in a semi
quantitative evaluation of the level of over-expression.
To evaluate the amount of lymphocytes in the CXCR4 positive
population in the tumor cell suspension, cells were co-incubated
Figure 1. Schematic representation of the integrated logistics made possible by using a targeting hybrid imaging agent. A) Analysis
of tumor biopsy samples using the fluorescent beacon of the imaging agent using flow cytometry. B) Non-invasive tumor visualization using SPECT/
CT after radiolabeling of the hybrid agent. Fluorescence imaging enables intraoperative surgical guidance. C) Ex vivo evaluation of tracer distribution
using fluorescence imaging and –microscopy after excision of the tumor.
doi:10.1371/journal.pone.0048324.g001
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(CD45-PE; 1:200; eBioscience). CXCR4 positive lymphocytes
were defined as cells that were both CXCR4 positive (CXCR4
ba-
sal, CXCR
+ and/or CXCR4
++) and CD45 positive. The total
percentage of CXCR4 positive lymphocytes was determined using
the following formula: (CD45
+ population within the CXCR4
positive population / total amount of CXCR4 positive
cells)6100%. The different CXCR4 positive populations were
selected and the presence of lymphocytes in each population was
determined in a similar manner as used for the whole population:
(CD45
+ population within the selected CXCR4 positive popula-
tion / total amount of cells in the selected population)6100%.
Statistics were performed using a standard T-test.
Confocal imaging of fresh tumor slices
For direct ex vivo evaluation of CXCR4 staining, 4T1 (n=3) and
late stage MIN-O (n=3) tumor bearing mice were sacrificed and
the tumor was removed. Next, the tumor was cut into thin tissue
slices which were then incubated with MSAP-Ac-TZ14011 (1:200
in MEM medium) for 1 hour at 4uC under dark conditions.
For comparison, 4T1 (n=3) and late stage MIN-O (n=3)
tumor bearing mice were intravenously injected with 50 mg
MSAP-Ac-TZ14011. Twenty-four hours after injection, mice
were sacrificed where after the tumor was removed and cut into
thin slices.
Before analysis using the Leica TCS SPII AOBS confocal
microscope (Leica Microsystems), slices were incubated with
DAPI, washed thoroughly with PBS and placed on 24 mm ø
glass coverslips. Non-incubated tumor slices were used as negative
control. Images were acquired at 37uC following excitation at
633 nm at 106 and 636 magnification. Emission was collected
from 650–725 nm. DAPI was excited at 405 nm and emission was
collected from 409–468 nm. Images were analysed using Leica
Confocal Software (Leica Microsystems).
Immunohistochemistry (IHC)
Formalin fixed paraffin embedded MIN-O or 4T1 tumor tissue
sections were stained according to the protocol previously reported
by van den Berg et al. [18] with a monoclonal anti-CXCR4
antibody (Rat-anti-CXCR4 clone 2B11 1:100; BD Biosciences).
Images were obtained at 406 magnification. Membranous
staining was assessed as previously reported [19]. The ratio
between the MIN-O and 4T1 tumor lesion was determined by
dividing the percentage of membranous staining in the MIN-O
tumor lesions by the percentage of membranous staining in the
4T1 tumor lesions. Statistics were performed using a standard T-
test.
In vivo imaging
Tumor bearing mice (n=5 for intermediate stage MIN-O; 100–
400 mm
3) lesions and n=5 for late stage 4T1 tumor lesion
(,400 mm
3)) were injected intravenously with 50 mg
111In-MSAP-
Ac-TZ14011 (10 MBq). SPECT/CT scans were conducted on a
preclinical SPECT/CT scanner (Nanospect; Bioscan) 24 hours
post injection. After acquisition, the CT data was reconstructed
using a cone-beam filtered back projection and SPECT data were
reconstructed iteratively with HiSPECT software (Scvis GmbH).
Signal intensities were analyzed using the InVivoScope post-
processing software (Bioscan Inc.). For further details, see van
Leeuwen et al. [25]. After SPECT/CT imaging, mice were
sacrificed. Tumor-to-muscle ratios were determined after mea-
surement of radioactivity as previously reported [19].
In vivo fluorescence imaging was conducted on the IVIS 200
camera (Xenogen Corp.) using Living Imaging Acquisition and
Analysis software (Xenogen Corp.). Images were acquired with
standard Cy5.5 (excitation 615–665 nm and emission 695–
770 nm) settings. Fluorescent content was measured in photons/
sec/cm
2.
Results
To set up an analytical method that can be applied for screening
of fresh biopsy specimens, cell suspensions of freshly obtained
tumor segments were prepared. After incubation of the tumor
derived cell suspensions with MSAP-Ac-TZ14011, flow cytometric
analysis revealed differences in fluorescent intensity levels between
the samples.
CXCR4 expression levels in MIN-O and 4T1 tumor lesions
In the MIN-O tumor lesions the mean fluorescence intensity
ratio (MFIR) of all stained cells increased from 165.5613.8 in
early stage to 367.9622.4 in late stage MIN-O lesions (for MFIR
values see Table 1). Overall, the MFIR found in the MIN-O
lesions is 3-fold (range 1.8–4) higher than in the 4T1 tumor lesions
(MFIR 91.5614.4; p,0.001; Table 1). This result is comparable
Figure 2. Structure of MSAP-Ac-TZ14011.
doi:10.1371/journal.pone.0048324.g002
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after flow cytometric assessment using the anti-CXCR4 antibody
2B11-PE [19]. Comparable ratios were also found when
comparing ratios found with MSAP-Ac-TZ14011 based flow
cytometry (Table 1) to quantified membranous staining (IHC) in
MIN-O and 4T1 tumor lesions.
Identification of individual cell populations
IHC revealed increasing but heterogeneous membranous
staining for CXCR4 in the MIN-O lesions (Table 1, Fig. 3). Flow
cytometric analysis enabled identification of different CXCR4
expressing cell populations after incubation with MSAP-
AcTZ14011
.(Fig. 4). As incubation occurred at 4uC, these
populations were differentiated based on the cell membrane
associated binding of the imaging agent. Fig. 4A shows that besides
a low percentage of CXCR4 negative cells (CXCR4
2 mean
13.262.6), three distinct populations were evident; CXCR4
basal
(mean 58.963.7), CXCR4
+ (mean 367.3647.0) and CXCR4
++
(mean 2197.46413.3).
The different cell populations were found in the MIN-O lesions
as well as in the 4T1 tumor specimens. The increase in
fluorescence intensity between the different populations was
determined by calculating the MFIR between the CXCR4
basal
and the CXCR4
+ or CXCR4
++ population. This resulted in a
7.861.2-fold higher ratio in the CXCR4
+ and a 47.0610.4-fold
higher ratio in the CXCR4
++ population compared to the
CXCR4
basal population. Carlisle et al. [26] reported comparable
differences in fluorescent intensities when comparing several cell
lines with different levels of CXCR4 expression. As such it appears
that during tumor progression different CXCR4 positive cell
populations exist within the tumor.
Further analysis of the results obtained with flow cytometry
revealed that the percentage of CXCR4
basal cells was highest in
the 4T1 tumor samples and that in the MIN-O lesions this
percentage of cells decreased during lesion progression (Table 2).
The percentage of strongly CXCR4 positive (CXCR4
+ and
CXCR4
++) cells increased from 68.661.5% in early stage MIN-O
lesions to 86.660.9% and 93.060.7% in intermediate and late
stage MIN-O lesions, respectively (Table 2). Furthermore, the
percentage of strongly CXCR4 positive cells was significantly
higher in all stages of MIN-O progression compared to the
percentage found in the control 4T1 tumor lesions (44.666.0%;
p,0.001).
In the MIN-O lesions the percentage CXCR4
+ and CXCR4
++
cells varied during tumor progression (Fig. 4A). In the early stage
MIN-O lesions 38.462.3% of the cells was CXCR4
+ and
30.362.0% of the cells was CXCR4
++. Intermediate stage lesions
showed a similar expression pattern, however, the percentage of
CXCR4
+ cells increased to 53.562.8%, whereas in late stage
lesions the percentage of CXCR4
+ cells had decreased to
12.961.0%. A 2.5-fold (range 2.4–2.6) increase in CXCR4
++
cells could be seen in the late stage lesions when compared to the
intermediate and early stage lesions (80.061.4% vs. 33.163.2%
and 30.362.0%, respectively) (Table 2).
Identification of the amount of CXCR4 expressing
lymphocytes
CXCR4 is not only expressed by tumor cells, but can also be
expressed by native immune cells such as lymphocytes [27]. As the
latter can also be present in tumor lesions [19], a control staining
for lymphocytes to exclude over- or underestimation of the
amount of CXCR4 positive tumor cells is required. Co-incubation
with both MSAP-Ac-TZ14011 and an anti-CD45 antibody were
used to determine the amount of lymphocytes (CD45
+) that were
CXCR4 positive. Flow cytometric analysis revealed that the
percentage of CD45
+ lymphocytes was highest in the 4T1 tumor
cell suspensions (9.95%). On the contrary, in the MIN-O lesions,
the amount of CD45
+ lymphocytes was very low, and only
increased slightly from 1.0% in early stage to 1.2% in intermediate
and 1.3% in late stage lesions.
Co-staining could be used to specify which CXCR4 positive
populations contained the CD45
+ cells (Fig. 4C–F) by differenti-
ating between the different CXCR4 expressing cell populations (x-
axis) and the CD45 expression of the cells (y-axis). In the MIN-O
lesions concomitant staining between CXCR4 and CD45 was
mainly seen in the CXCR4
basal population (Fig. 4C–E) whereas in
the 4T1 controls CD45
+ cells were predominantly present in the
CXCR4
basal and CXCR4
+ populations (Fig. 4F). Although clearly
detectable, the percentages of CD45
+ cells found in the different
MIN-O and 4T1 tumor tissue samples are not likely to influence
the CXCR4 based discrimination between the MIN-O and the
4T1 tumor lesions.
Fluorescence IHC of CXCR4 expression
Similar to Ac-TZ14011-FITC [17], MSAP-Ac-TZ14011 could
also be used during fluorescence IHC applications. Confocal
microscopy at 37uC after ex vivo incubation (at 4uC) of fresh tumor
slices revealed both membranous and cytoplasmic staining
throughout the late stage MIN-O tumor lesion (Fig. 5A I and
5A II). In the 4T1 control lesions hardly any fluorescence staining
could be observed under the same conditions. Accumulation in
4T1 tumor lesions was comparable to the image in Figure 6D.
In vivo SPECT/CT and fluorescence imaging
Flow cytometric and fluorescence IHC data combined allowed
an accurate differentiation between predominantly CXCR4-basal
4T1 tumors and CXCR4-positive MIN-O lesions. In vivo, MIN-O
lesions characterized as mainly CXCR4
+/CXCR4
++ at initial
Table 1. Evaluation of CXCR4 expression with flow cytometric analysis and IHC.
MFIR CXCR4
+ and CXCR4
++
population Ratio MFIR MIN-O/4T1
Ratio membranous staining MIN-O/
4T1 (ex vivo)
MIN-O (early stage) 165.5613.8 1.8 1.1
MIN-O (intermediate stage) 329.6633.6 3.6 3.5
MIN-O (late stage) 367.9622.4 4.0 5.5
4T1 91.5614.4 - -
For MIN-O tumor tissue, 6 biopsy samples per stage were evaluated. Also, n=6 4T1 biopsy samples were assessed. All samples were evaluated in triplicate. MFIR: mean
fluorescent intensity ratio. Ratio of membranous staining calculated from data reported in [15].
doi:10.1371/journal.pone.0048324.t001
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CT imaging after intravenous injection of
111In labeled MSAP-Ac-
TZ14011 (
111In-MSAP-Ac-TZ14011). The 4T1 tumor lesions
showed no tracer accumulation at the same imaging settings
(Fig. 6A).
Evaluation of the
111In-MSAP-Ac-TZ14011 uptake levels in the
tumor lesions (%ID/g) resulted in a tumor-to-muscle ratio that was
3.8 times higher in the late stage MIN-O lesions (4.5560.67) as
compared to the 4T1 lesions (1.2060.12; Table 3). Biodistribution
for both models was conform previously reported results [15].
Quantification of the fluorescence signal intensities in these tumor
lesions revealed results comparable to the radioactivity measure-
ments (Table 3). The signal intensity was 4.2 times higher in the
late stage MIN-O lesions compared to the 4T1 tumor lesions
(1.09610
961.7610
8 vs. 2.5610
863.8610
7 photons/sec/cm
2
respectively) (Fig. 6B). This 4-fold difference seen with both
SPECT/CT and fluorescence imaging was in accordance with the
differences found in membranous CXCR4 expression (Table 1).
Ex vivo assessment of tracer distribution
Although conventional IHC still acts as ‘‘golden standard’’ for
the ex vivo evaluation (see Table 1), the fluorescent labels can also
be detected ex vivo using a fluorescence microscope. Ex vivo
fluorescence assessment of the tracer distribution in fresh tumor
tissue segments following the systemic injection of MSAP-Ac-
TZ14011 (24 hours prior to tumor excision) predominantly
revealed accumulation of the imaging agent in the cytoplasm of
the MIN-O lesions (Fig. 5A I and II and Fig. 6D), something that
was not seen in the 4T1 control samples (Fig. 6D). Cytoplasmic
Figure 3. CXCR4 staining using immunohistochemistry. Membranous staining of fixed tumor tissue slices after incubation with the anti-CXCR4
antibody 2B11 in A) early, B) intermediate, C) late stage MIN-O tumor lesions and D) 4T1 control tumors (406magnification).
doi:10.1371/journal.pone.0048324.g003
Figure 4. Fluorescence based fresh tumor biopsy analysis after incubation with MSAP-Ac-TZ14011. A) CXCR4 staining pattern in early
(black), intermediate (red) and late stage (blue) MIN-O biopsy samples. B) CXCR4 staining pattern in 4T1 biopsy samples. Non-incubated control
samples are depicted in grey. C–F) Analysis of CD45 expression in CXCR4 positive cells in early, intermediate and late stage MIN-O tumor lesions and
4T1 tumor lesions. For percentages of populations with different CXCR4 expression, see Table 2.
doi:10.1371/journal.pone.0048324.g004
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receptors over time at 37uC [17].
Compared to systemic tracer administration, differences in
staining patterns were observed after direct (ex vivo) incubation of
tumor tissue samples with MSAP-Ac-TZ14011 (Fig. 5A) (Fig. 4B).
Direct, ex vivo, incubation of the tumor tissue will probably enable
visualization of ‘‘all’’ CXCR4 positive cells present, systemic
administration will most certainly only stain cells that could be
reached by the tracer via the vascular network.
Evaluation of the anb3-integrin expression in late stage MIN-O
lesions and 4T1 tumor lesions previously revealed that the degree
of angiogenesis in both MIN-O and 4T1 tumor lesions is similar
[19]. The lesions are overall well perfused, but some regions
contained more and larger blood vessels than others. This
heterogeneity in the vascular physiology will likely be of influence
on the distribution of the tracer throughout the tumor.
Discussion
Imaging applications using hybrid tracers are rapidly emerging
[28–31] and have already been successfully applied in clinical
studies facilitating integrated pre- and intraoperative imaging of
sentinel nodes [10–15]. By adding a receptor targeting moiety, the
utility of hybrid imaging agents can be expanded to pre-imaging
screening of biomarker expression levels and subsequent (imaging)
target selection.
In a previous comparison of currently available imaging agents
for CXCR4, Ac-TZ14011 showed great potential in fluorescence
imaging and hybrid imaging applications [17]. Ac-TZ14011 was
shown to bind selectively to CXCR4 and could be used to visualize
CXCR4 positive tumor lesions in vivo [18,19,21,22,32]. It must be
noted that MSAP-Ac-TZ14011 derivatives are currently the only
hybrid imaging agents available for CXCR4 targeting [17]. For in
vivo imaging experiments with this tracer the use of a relatively low
specific activity was shown to be beneficial for tumor visualization
[17]. We have previously demonstrated that tumor models, which
more accurately represent the modest five-fold CXCR4 over-
expression found in the clinical situation, such as the MIN-O
model used in this study, better represent the clinically found
CXCR4 expression levels in tumors [17]. As a result the in vivo
SPECT/CT images obtained in this study (Figure 6) provide less
of a black and white discrimination between CXCR4 positive
tumors and their background, than can be obtained using
transfected tumor cells with extremely high levels of CXCR4
expression [17].
The hybrid nature of the CXCR4 targeting imaging agent
MSAP-Ac-TZ14011 has allowed us to successfully demonstrate
the concept of integrating target selection in fresh (biopsy) tumor
tissue with in vivo imaging and ex vivo microscopic validation (Fig. 1),
all using a single imaging agent.
Similar to the in vitro evaluation of fluorescently labeled imaging
agents [21,22], flow cytometriy could be used to analyze the level
of CXCR4 expression in the tumor cell suspensions. In this
application incubation with MSAP-Ac-TZ14011 allowed effective
discrimination between MIN-O (stages) and 4T1 tumor lesions
using the fluorescent label of the targeting hybrid imaging agent
(Fig. 4 and Table 2). These findings were further confirmed with
IHC (Table 2), in vivo SPECT/CT (using the radiolabel) and
fluorescence imaging (Fig. 6); the ratio between the late stage
MIN-O and similarly sized 4T1 control lesions was comparable
with all visualization methods.
Flow cytometry is already being used in a clinical setting for
applications such as diagnosis of leukemia and lymphoma [33–36]
and dependent on the analyzer used, flow cytometry enables
assessment of up to 15 cell surface parameters in one sample [35].
Even the small early stage tumors (,100 mm
3), which are
comparable in size with human biopsy samples, contain sufficient
cells for characterization of multiple samples. In this study co-
incubation of MSAP-Ac-TZ14011 and an anti-CD45 antibody
showed that at least two markers could be simultaneously
evaluated in fresh tumor specimens and that the presence of
native immune cells in the tumor tissue could be assessed. Addition
of such a control staining can be used to exclude over- or
Table 2. Staining percentages of populations with different CXCR4 expression.
% CXCR4
2 % CXCR4
basal % CXCR4
+ % CXCR4
++ % CXCR4
+/++
MIN-O (early stage) 6.960.8 25.960.8 38.462.3 30.362.0 68.661.5
MIN-O (intermediate stage) 2.960.3 11.460.7 53.562.8 33.163.2 86.660.9
MIN-O (late stage) 3.060.5 4.760.5 12.961.0 80.061.4 93.060.7
4T1 1.260.4 56.165.3 27.062.3 18.364.3 44.666.0
doi:10.1371/journal.pone.0048324.t002
Figure 5. Evaluation of freshly isolated MIN-O tumor slices. A)
ex vivo incubation with MSAP-Ac-TZ14011 and B) after intravenous
injection of MSAP-Ac-TZ14011 twenty-four hours prior to evaluation of
the tissue. I: 106magnification. II) 636magnification. Signal emitted by
MSAP-Ac-TZ14011 is depicted in magenta and DAPI (blue) was used to
visualize the cell nucleus.
doi:10.1371/journal.pone.0048324.g005
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For future applications in cancer management it will be possible to
set up such screens using a number of biomarker targeting imaging
agents simultaneously. By labeling each agent with a different
fluorescent dye a tailored selection of the most prominently
available receptor proteins suitable for imaging can then be made.
The method of staining and the fact that perfusion is essential for
good visualization in vivo should, however, be taken into account
when comparing flow cytometry/IHC to in vivo imaging results.
In agreement with the results obtained with flow cytometric
analysis after incubation with MSAP-Ac-TZ14011, we have
previously demonstrated that CXCR4 expression in MIN-O
lesions is heterogeneous and that the degree of membranous
staining of CXCR4 at IHC increases with lesion progression [19].
This increase in membranous staining was in concordance with
the increase in uptake of
111In-Ac-TZ14011 during MIN-O lesion
progression [19]. With IHC only total staining percentages can be
obtained, whereas flow cytometry can also be used for the accurate
evaluation of cell populations with different expression levels
within one tumor sample (Table 1; [26]). As fluorescence
intensities vary according to receptor expression on the cells, the
(semi-quantitative) signal intensity levels can be directly, linked to
receptor CXCR4 expression levels [37]. Flow cytometric analysis
after incubation of the tumor cell suspensions with MSAP-Ac-
TZ14011 underlined that CXCR4 positivity increased during the
progression of MIN-O lesions. An increase in the percentage of
CXCR4
+ cells seemed to mark the transition into intermediate
stage lesions. Concurrently, invasive late stage lesions mainly
contained CXCR4
++ cells, which is in line with the clinically
reported higher expression of CXCR4 in more invasive types of
breast cancer [6].
One can envision that besides the ability to select the most
appropriate targeting imaging procedure, the level of over-
expression of a biomarker that is associated with e.g. malignancy
of a tumor [8,38,39], may also influence clinical decision-making.
For example, CXCR4 expression is linked to a higher tendency to
metastasize and higher levels of CXCR4 expression have been
found in (distant) metastasis compared to the primary tumor [38].
It has also been proposed that CXCR4 expression levels can be
used to select subsets of tumor lesions that show a more aggressive
biological behavior [40]. Furthermore, Chu et al. [39] previously
proposed that CXCR4 expression levels allow for the identifica-
Figure 6. Non-invasive imaging. A) SPECT/CT imaging after intravenous injection of
111In-MSAP-Ac-TZ14011. B) in vivo and C) ex vivo fluorescence
imaging. D) fluorescence microscopy (106magnification). Intermediate stage MIN-O: top images. Late stage 4T1: bottom images.
doi:10.1371/journal.pone.0048324.g006
Table 3. In vivo imaging: Ratio between signal in late stage
MIN-O and 4T1 tumor lesions.
Ratio signal in MIN-O/ 4T1
Radioactivity (%ID/g) 3.8
Fluorescence (photons/sec/cm
2)4 . 2
doi:10.1371/journal.pone.0048324.t003
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disease, even within patient groups with an initial good prognosis.
It will be interesting to investigate what the influence of the
presence of CXCR4
++ cells will be on metastatic ability of
metastatic MIN-O tumor models [23]. Herein the orthotopic
MIN-O transplantation model used in this study [24,41] serves as
an ideal model; besides the evaluation of tumor progression into
an invasive phenotype, MIN-O strains that metastasize have also
been described [23].
The main goal of this study was to evaluate the concept of using
biopsy tissue specimens for a personalized selection of the most
optimal targeted imaging approach. Obviously, the concept
described above is not limited to the targeting of CXCR4. A
hybrid version of an imaging agent targeting a biomarker of choice
can be used. Possibly, also a cocktail of imaging agents can be used
for the simultaneous assessment of several markers at once. Use of
different fluorescent dyes and/or radioactive isotopes will then
enable discrimination between biomarkers. In this way, the
screening and in vivo imaging data can still be used for accurate
staging of the tumor lesions. The latter will not be possible when
identically labeled imaging agents are used.
Conclusions
Hybrid imaging agents can be used during the different steps
encountered in the clinical management of cancer. Comparable
quantitative results have been obtained during target selection in
biopsy tissue (flow cytometry), in vivo imaging (SPECT/CT and
fluorescence imaging) and during pathological validation (ex vivo
microscopy) of the surgically excised tissue (ex vivo microscopic
analysis). Incubation with MSAP-Ac-TZ14011 enabled accurate
staging of MIN-O lesion progression via the CXCR4 expression
pattern of the lesions. Although only CXCR4 was used in this
proof of concept study, this approach can readily be expanded to
other targeting hybrid imaging agents and will help increase the
clinical applicability of tumor specific imaging approaches.
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